Profusa makes tiny bio-integrated sensors, like the Lumee Oxygen Platform, that live under your skin and continuously track oxygen and other health markers, feeding AI-driven insights for managing diabetes and critical limb ischemia.
No revenue is reported, and the company is burning cash with net losses of USD 0.04B in 2025 and USD 0.01B in 2024. There is no visible product sales or recurring service income yet.
Profusa's sensor technology is novel and hard to copy, but it lacks a commercial track record and faces competition from established players like Dexcom and Abbott, whose continuous glucose monitors already dominate the market. The moat is weak because no dura
Key events, in time order
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
